Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Joseph Vinhais sold 6,800 shares of Integra Lifesciences stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $54.13, for a total value of $368,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Integra Lifesciences Holdings Corp (NASDAQ IART) traded up $0.92 during trading on Monday, hitting $55.77. The stock had a trading volume of 384,321 shares, compared to its average volume of 510,734. The firm has a market cap of $4,305.41, a PE ratio of 68.01, a P/E/G ratio of 1.69 and a beta of 0.65. Integra Lifesciences Holdings Corp has a fifty-two week low of $40.51 and a fifty-two week high of $56.42. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85.
Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.08. The business had revenue of $368.60 million for the quarter, compared to analysts’ expectations of $362.64 million. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The business’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS. research analysts forecast that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on IART shares. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. BidaskClub upgraded Integra Lifesciences from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Jefferies Group reiterated a “buy” rating and issued a $63.00 price objective on shares of Integra Lifesciences in a report on Thursday, March 1st. Cantor Fitzgerald restated a “neutral” rating and set a $52.00 target price on shares of Integra Lifesciences in a report on Friday, January 5th. Finally, Bank of America cut Integra Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the stock. Integra Lifesciences currently has an average rating of “Hold” and an average target price of $54.18.
ILLEGAL ACTIVITY WARNING: “Integra Lifesciences Holdings Corp (IART) VP Sells $368,084.00 in Stock” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/12/integra-lifesciences-holdings-corp-iart-vp-sells-368084-00-in-stock.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.